Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?
Purushotham
Arnie
A
King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UK.
Pinder
Sarah
S
Cariati
Massi
M
Harries
Mark
M
Goldhirsch
Aron
A
D001943:Breast Neoplasms / Q000188:drug therapy*; D018275:Carcinoma, Lobular / Q000188:drug therapy*; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*
D004967:Estrogens; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen